Gilead Sciences (NASDAQ:GILD) is set to report fourth-quarter earnings on February 10, 2026, following positive developments in its Phase 3 trial for Trodelvy, which bolstered investor confidence. The company recently outperformed the S&P 500, with shares rising 1.72% to $141.95. Analysts have reacted positively, with UBS and BMO Capital raising their price targets to $155 and $150, respectively, reflecting Gilead's strong revenue growth to $7.8 billion, despite a concerning drop in operating margins.
“Gilead · are due to report · fourth-quarter earnings results · soon”
“Gilead Sciences (GILD) · outpaced · S&P 500's daily loss · 0.43%”
“Gilead · is part of · Dow Jones biotech stocks · true”
“Gilead · is due to report · fourth-quarter earnings results · true”
“Gilead Sciences, Inc. (NASDAQ:GILD) · is · among the most profitable healthcare stocks to buy”
“UBS · lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) · from $145 to $155”
“UBS · maintained a rating on Gilead Sciences, Inc. (NASDAQ:GILD) · Buy”
“BMO Capital · raised its target on Gilead Sciences, Inc. (NASDAQ:GILD) · to $150 from $135”
“BMO Capital · reiterated a rating on Gilead Sciences, Inc. (NASDAQ:GILD) · Outperform”
“Gilead Sciences, Inc. (NASDAQ:GILD) · is · a California-based biopharmaceutical company”
“Gilead Sciences, Inc. (NASDAQ:GILD) · specializes in · medicines aimed at unmet needs”
“Gilead Sciences, Inc. (NASDAQ:GILD) · provides · a range of products as solutions for HIV/AIDS, COVID-19, viral hepatitis, oncology, pulmonary arterial hypertension, and serious invasive fungal infections”
